A Phase 1/2 interventional study of HiCM-188 therapy in Heart Failure, sponsored by HELP Therapeutics Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.
Sponsored by HELP Therapeutics Co., Ltd. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 375 studies in Heart Failure with a site in China — 162 open to participants now, 182 under way, 18 of them phase 3. Heart Failure · China.
Among the 375 studies in Heart Failure with a site in China, this one is the 213th largest by planned enrollment of the 246 interventional ones that give a count, is one of 42 that started in 2023, is one of 14 in phase 1/2, reaches primary completion later than 80 of the 181 other live ones, and was the 233rd registered.
6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.
Browse Heart Failure studies →162 of the 375 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 65+
Jiangsu Taizhou People's Hospital · Sites in China
Ages 65+ · Healthy volunteers
AstraZeneca · Sites in China, United States, Argentina and 29 more countries
Ages 18+
Pulnovo Medical, Inc. · Sites in China, United States
Ages 18–85
Tasly Pharmaceutical Group Co., Ltd · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
375 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 44 · Phase 3 49 · Phase 4 29
First in 1983; this study’s year is marked. 42 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 127 across the 246 interventional studies, 540 across the 129 observational. Of the 115 that completed or were terminated, 33 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
109 of 375 have an industry lead sponsor. The 10 most frequent:
HELP Therapeutics Co., Ltd. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
HELP Therapeutics Co., Ltd. has 4 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
46 of the studies in Heart Failure with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT07496372Phase 3HELP Therapeutics Co., Ltd.A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV) | 2027-06-30 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06024746Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | 2027-11 |
| NCT06927440Shanghai Jiao Tong University School of MedicineNational Multicenter Registry for Pediatric End-Stage Heart Failure in China | 2026-11-30 |
Add all 46 to your calendar (.ics) → With an account.
Among the 375 studies in Heart Failure with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to evaluate the feasibility, safety and efficacy of intramyocardial injection of human induce pluripotent stem cell-derived cardiomyocytes (HiCM-188) during coronary artery bypass grafting (CABG) surgery in patients with severe chronic ischemic heart failure.
This is a single center, open-label, three-group dose-escalation (phase I) study followed by dose-extension (phase IIa) study in up to 36 severe ischemic heart failure patients. It is estimated that up to 18 phase I patients will be received HiCM-188 intramyocardial injection during CABG surgery. The maximum number of subjects after dose escalation and dose extension studies in each dose group is 12. All the subjects need take immunosuppressant after transplantation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intramyocardial injection of HiCM-188 (50 million) during CABG surgery.
Drug: HiCM-188 therapy
Intramyocardial injection of HiCM-188 (150 million) during CABG surgery.
Drug: HiCM-188 therapy
Intramyocardial injection of HiCM-188 (450 million) during CABG surgery.
Drug: HiCM-188 therapy
Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes (HiCM-188) during coronary artery bypass grafting surgery
The incidence of major Serious Adverse Events (SAE)
The incidence of major Serious Adverse Events (SAE) within the first month after surgery, including pericardial tamponade, nonfatal myocardial infarction, stroke, and all-cause death
Time frame: Within the first month after surgery
Grade 4 or above arrhythmias Related to HiCM-188 Cell Therapy
Grade 4 or above arrhythmias associated with the HiCM-188 therapy within the first month after surgery
Time frame: Within the first month after surgery
The incidence of tumor
assessed by PET whole-body imaging at baseline and 12 months after HiCM-188 therapy
Time frame: 12 months after surgery
Left ventricular geometry as assessed by cardiac magnetic resonance imaging (MRI)
Left ventricular wall thickness, interventricular septum thickness
Time frame: Baseline, 6 and 12 months after surgery
Size of myocardial infarction as assessed by MRI
Size of myocardial infarction
Time frame: Baseline, 6 and 12 months after surgery
Ventricular wall motion as assessed by MRI
Ventricular wall motion
Time frame: Baseline, 6 and 12 months after surgery
Left ventricular ejection fraction as assessed by MRI
Left ventricular ejection fraction
Time frame: Baseline, 6 and 12 months after surgery
Cardiac Volumes as assessed by MRI
Left ventricular end-diastolic volume (LVEDV), Left ventricular end-systolic volume (LVESV) and Stroke Volume (SV)
Time frame: Baseline, 6 and 12 months after surgery
Cardiac output (CO) as assessed by MRI
Cardiac output (CO)
Time frame: Baseline, 6 and 12 months after surgery
End-diastolic myocardial mass as assessed by MRI
End-diastolic myocardial mass
Time frame: Baseline, 6 and 12 months after surgery
Left ventricular ejection fraction (LVEF) as assessed by Echocardiography
Left ventricular ejection fraction
Time frame: Baseline, 6 and 12 months after surgery
Fractional shortening (FS) as assessed by Echocardiography
Fractional shortening
Time frame: Baseline, 6 and 12 months after surgery
Left ventricular dimensions as assessed by Echocardiography
Left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter(LVESD)and left atrial diameter
Time frame: Baseline, 6 and 12 months after surgery
Cardiac Volumes as assessed by Echocardiography
Left ventricular end- diastolic volume (LVEDV) and Left ventricular end-systolic volume(LVESV)
Time frame: Baseline, 6 and 12 months after surgery
Mitral valve inflow spectrum(E/A) as assessed by Echocardiography
Mitral valve inflow spectrum (E/A)
Time frame: Baseline, 6 and 12 months after surgery
Longitudinal strain as assessed by Echocardiography
Longitudinal strain
Time frame: Baseline, 6 and 12 months after surgery
Myocardial viability as assessed by SPECT
Myocardial viability
Time frame: Baseline, 6 and 12 months after surgery
Myocardial blood flow as assessed by SPECT
Myocardial blood flow
Time frame: Baseline, 6 and 12 months after surgery
NT-proBNP Levels
The changes of NT-proBNP Levels
Time frame: Baseline, 6 and 12 months after surgery
6-minute walking distance
The changes of 6-minute walking distance at 6M and 12M after HiCM-188 therapy
Time frame: Baseline, 6 and 12 months after surgery
New York Heart Association (NYHA) functional classification
The changes of New York Heart Association (NYHA) functional classification at 6M and 12M after HiCM-188 therapy
Time frame: Baseline, 6 and 12 months after surgery
Changes of Quality of Life (QoL) as assessed by Minnesota Living with Heart Failure Questionnaire (MLHFQ)
The MLHFQ is a self-administered disease-specific outcome measure instrument for patients with heart failure (HF), comprising 21 items rated on Likert scales, representing different degrees of impact of HF on QoL. The MLHFQ scores are on a range of 0-105, in which higher scores reflect better health status.
Time frame: Baseline, 6 and 12 months after surgery
Changes of Quality of Life(QOL) as assessed by 36-Item Short Form Survey (SF-36)
The 36-Item Short Form Survey(SF-36) is a self-administered outcome measure instrument that comprises 36 items grouped into 8 dimensions: limitations in physical activities because of health problems, limitations in social activities because of physical or emotional problems, limitations in usual role activities because of physical health problems, bodily pain, general mental health, limitations in usual role activities because of emotional problems, vitality, general health perceptions. The SF-36 scores are on a range of 0-100, in which higher scores reflect better health status.
Time frame: Baseline, 6 and 12 months after surgery
Started Sep 2023 (actual). Primary completion is estimated for Nov 2026, 38 months after the start.
Of 43 phase 1/2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 48. This study's planned 38 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HICM-188
HELP Therapeutics Co., Ltd.